Therapeutic | Navicixizumab |
Target 1 | DLL4 |
Heavy Chain 1 | QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS |
Light Chain 1 | DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | VEGFA |
Heavy Chain 2 | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS |
Light Chain 2 | DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific mAb |
Isotype | G2 |
Highest Clinical Trial (Jan '20) | Phase-I |
Estimated Status (Jan '20) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | OncoMed Pharmaceuticals |
Conditions Approved | na |
Conditions Active | Fallopian tube cancer, Ovarian cancer, Peritoneal cancer, Solid tumours |
Conditions Discontinued | Colorectal cancer |
Notes |